WallStSmart

Merck & Company Inc (MRK)vsQuantum BioPharma Ltd. (QNTM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

QNTM

Avoid

16

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 2.5
Piotroski: 1/9Altman Z: -32.12
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for QNTM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

QNTM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

QNTM4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$25.15M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : QNTM

QNTM has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : QNTM

The primary concerns for QNTM are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

QNTM carries more volatility with a beta of 0.40 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Quantum BioPharma Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on developing transformative therapies targeting oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products and a strong emphasis on research and development, Quantum leverages advanced technologies to address unmet medical needs. The company’s strategic collaborations and experienced leadership contribute to its competitive edge, positioning it well for growth in the dynamic biopharmaceutical landscape. As the market for novel therapeutics expands, QNTM presents an appealing investment opportunity for institutional investors seeking exposure in this high-potential sector.

Visit Website →

Want to dig deeper into these stocks?